Relevant bibliographies by topics / Gert Hofmann / Journal articles

Journal articles on the topic 'Gert Hofmann'

To see the other types of publications on this topic, follow the link: Gert Hofmann.
Author: Grafiati
Published: 10 December 2022
Last updated: 28 January 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 26 journal articles for your research on the topic 'Gert Hofmann.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Hofmann, Michael. "For Gert Hofmann, Died 1 July 1993." Grand Street, no. 68 (1999): 118. http://dx.doi.org/10.2307/25008492.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Göttsche, Dirk. "Erinnerung und Zeitkritik bei Ingeborg Bachmann, Gert Hofmann und Botho Strauß." Germanica, no. 13 (December 31, 1993): 79–95. http://dx.doi.org/10.4000/germanica.2172.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Butler, Michael. "‘EIN HOFFNUNGSLOSER MORALIST’: SOME OBSERVATIONS ON THE NARRATIVE WORLD OF GERT HOFMANN." German Life and Letters 47, no. 3 (July 1994): 375–84. http://dx.doi.org/10.1111/j.1468-0483.1994.tb01546.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Dengler, Kathrin, and Uta Bittner. "WHAT DO WE MEAN BY TALKING ABOUT “VALUE(S)”? A REPLY TO SAARNI ET AL." International Journal of Technology Assessment in Health Care 28, no. 2 (April 2012): 195–96. http://dx.doi.org/10.1017/s026646231200013x.

Full text
Abstract:
In their article “Different methods for ethical analysis in health technology assessment: An empirical study” published inInternational Journal of Technology Assessment in Health Care, Volume 27 Number 4, Samuli I. Saarni, Annette Braunack-Mayer, Bjørn Hofmann, and Gert Jan van der Wilt present an empirical study about different methods for ethical analysis in health technology assessment (HTA). They claim that ethical analysis is an important issue which can highlight values inherent in a technology and value-decisions underlying a HTA process (4). Although their study is rich in detail; gives an interesting overview of casuistry, principlism, and axiological ethic frameworks; and make ethical evaluations within HTA more transparent, we suppose, one important point needs further serious discussion: the clarification of what is meant by “value.”
APA, Harvard, Vancouver, ISO, and other styles
5

Pinfold, Debbie. "'Das War Schon Einmal Da, Wie Langweilig!'?: 'Horspiel' and Narrative in the Work of Gert Hofmann (1931-1993)." German Life and Letters 52, no. 4 (October 1999): 475–89. http://dx.doi.org/10.1111/1468-0483.00147.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Fuchs, Anne. "Book Review: Gert Hofmann, Rachel MagShamhráin, Marko Pajevic and Michael Shields (eds): German and European Poetics after the Holocaust." Journal of European Studies 42, no. 2 (May 29, 2012): 208–10. http://dx.doi.org/10.1177/0047244112437134o.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

O’Brien, Traci S. "German and European Poetics after the Holocaust: Crisis and Creativity ed. by Gert Hofmann et al. (review)." Journal of Austrian Studies 45, no. 3-4 (2012): 186–88. http://dx.doi.org/10.1353/oas.2012.0019.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Schlant, Ernestine. "Gert Hofmann's "Die Denunziation"." German Studies Review 19, no. 3 (October 1996): 415. http://dx.doi.org/10.2307/1432525.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Krost, Heidrun, and Janine Hofmann. "„Beharrlichkeit zahlt sich aus“." Lebensmittel Zeitung 73, no. 20 (2021): 34. http://dx.doi.org/10.51202/0947-7527-2021-20-034.

Full text
Abstract:
Während einige Händler Craftbier bereits auf Sparflamme kochen, geht Globus in die Offensive und glaubt an die Strahlkraft des Nischen-Segments für die ganze Kategorie. Und der Händler tut es mit System. Janine Hofmann und Heidrun Krost
APA, Harvard, Vancouver, ISO, and other styles
10

Grunzweig, Walter. "Die vergebliche Enttrummerung beschadigter Kinderkopfe: Nationalsozialismus in den Werken Gert Hofmanns." German Studies Review 12, no. 1 (February 1989): 55. http://dx.doi.org/10.2307/1430290.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Scheide, William H. "Nochmals BWV 50 "Nun ist das Heil und die Kraft"." Bach-Jahrbuch 87 (March 8, 2018): 117–30. http://dx.doi.org/10.13141/bjb.v20011727.

Full text
Abstract:
Mit dem Artikel bringt der Autor sich erneut in die im BJ 1982 von ihm angestoßene, durch verschiedene Beiträge bereicherte Diskussion um BWV 50 ein (Links zu den zugehörigen Artikeln s.u.). Dabei geht er auf verschiedene zwischenzeitlich vorgebrachte Argumente zu Echtheitsfragen um das Werk ein. Hofmann und Stein sind der Ansicht, Bach sei der Komponist, Rifkin sieht Bach völlig unbeteiligt an der Komposition und Scheide vertritt die These, die überlieferte, doppelchörige Form des Werks sei die Bearbeitung einer Bach'schen Komposition durch einen Unbekannten. Der Autor verteidigt diesen Standpunkt in einer detaillierten Entgegnung auf einzelne Argumente der anderen Beiträger. Erwähnte Artikel: William H. Scheide: "Nun ist das Heil und die Kraft" BWV 50: Doppelchörigkeit, Datierung und Bestimmung. BJ 1982, S. 81-96 Klaus Hofmann: Bachs Doppelchor "Nun ist das Heil und die Kraft" (BWV 50). Neue Überlegungen zur Werkgeschichte. BJ 1994, S. 59-73 Klaus Stein: Stammt "Nun ist das Heil und die Kraft" (BWV 50) von Johann Sebastian Bach? BJ 1999, S. 51-66 Joshua Rifkin: Siegesjubel und Satzfehler. Zum Problem von "Nun ist das Heil und die Kraft" (BWV 50). BJ 2000, S. 67-86
APA, Harvard, Vancouver, ISO, and other styles
12

Hofmann, Klaus. ""Großer Herr, o starker König"." Bach-Jahrbuch 81 (February 2, 2018): 31–46. http://dx.doi.org/10.13141/bjb.v19951053.

Full text
Abstract:
Das Fanfarenthema der Solo-Trompete in J. S. Bachs Arie Großer Herr, o starker König aus dem Weihnachts-Oratorium, das Bach in wechselndem Erscheinungsbild in mehreren Kantaten und Orchesterwerken aufgreift, stammt nicht von ihm selbst, sondern geht auf einen Bläser-Signalruf aus dem frühen 18. Jahrhundert zurück. Es taucht auch in Kompositionen von J. J. Fux, H. I. F. Biber, M. P. de Montéclair und M. Haydn auf. Der Autor untersucht die Verwendung des Themas in der Musik vor, neben und nach Bach und gibt darüber hinaus einen Überblick über die unterschiedliche Verwendung, Funktion und Bedeutung von Fanfarenmusik in ihren verschiedenen Kontexten. (Dorothea Wagner, Quelle: Bibliographie des Musikschrifttums online) Vergleiche auch: Malcolm Boyd: Bach, Telemann und das Fanfarenthema. BJ 1996, S. 147-150 Klaus Hofmann: Nochmals: Bachs Fanfarenthema. BJ 1997, S. 177-180
APA, Harvard, Vancouver, ISO, and other styles
13

Paver, Chloe E. M. ""Als Hitler und der Tonfilm kamen": Cinematic, Technological, and Historical Narratives in Gert Hofmann's "Der Kinoerzahler"." Modern Language Review 97, no. 3 (July 2002): 632. http://dx.doi.org/10.2307/3737497.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Knapp, Thyra E. "“Beim Straucheln und beim Stürzen und beim Schreien”: Ekphrastic Representation and Identification in Gert Hofmann's Der Blindensturz." German Quarterly 84, no. 3 (July 2011): 328–43. http://dx.doi.org/10.1111/j.1756-1183.2011.00117.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Schulze, Hans-Joachim. "Rätselhafte Auftragswerke Johann Sebastian Bachs. Anmerkungen zu einigen Kantatentexten." Bach-Jahrbuch 96 (January 1, 2010): 69–93. http://dx.doi.org/10.13141/bjb.v20101881.

Full text
Abstract:
Die behandelten Kantaten sind Nach dir Herr, verlanget mich BWV 150, Schwingt freudig euch empor BWV 36c und Non sa che sia dolore BWV 209. BWV 150 wird anhand des enthaltenen Meckbach-Akrostychons zum einen fest in die Mühlhäuser Zeit 1707-1708 datiert, zum anderen als mögliches Auftragswerk des dort lebenden Dr. Conrad Meckbach betrachtet. BWV 36c wird anhand der gesicherten Datierung und verschiedener textlicher Bezüge eine Zuordnung zu einem möglichen Huldigungsempfänger versucht, jedoch keiner möglichen Version der Vorzug gegeben. BWV 209 wird nach längerer Diskussion verschiedener in Betracht zu ziehender Aspekte als Auftragswerk zu Ehren Lorenz Albrecht Becks. Ein Epilog betrachtet die Freiherren von Lyncker als mögliche Mäzene Becks. Erwähnte Artikel: Hermann von Hase: Breitkopfsche Textdrucke zu Leipziger Musikaufführungen zu Bachs Zeiten. BJ 1913, S. 69-127 Georg Schünemann: J. G. Walther und H. Bokemeyer. BJ 1933, S. 86-118 Andreas Glöckner: Neuerkenntnisse zu Johann Sebastian Bachs Aufführungskalender zwischen 1729 und 1735. BJ 1981, S. 43-76 Harald Schieckel: Johann Sebastian Bachs Auflösung eines Kanons von Teodoro Riccio. BJ 1982, S. 125-127 Hans-Joachim Schulze: "Entfernet euch, ihr heitern Sterne", BWV Anh. 9. BJ 1985, S. 166-168 Andreas Glöckner: Zur Echtheit und Datierung der Kantate BWV 150 "Nach dir, Herr, verlanget mich". BJ 1988, S. 195-203 Klaus Hofmann: "Wo sind meine Wunderwerke" - eine verschollene Thomasschulkantate Johann Sebastian Bachs? BJ 1988, S. 211-218 Klaus Hofmann: Alte und neue Überlegungen zur Kantate "Non sa che sia dolore" BWV 209. BJ 1990, S. 7-26 Ares Rolf: Die Besetzung des sechsten Brandenburgischen Konzerts. BJ 1998, S. 171-182 Michael Maul: Johann Sebastian Bachs Besuche in der Residenzstadt Gera. BJ 2004, S. 101-120 Ernst Koch: Johann Sebastian Bachs Musik als höchste Kunst. Ein unbekannter Brief aus Leipzig vom 9. August 1723. BJ 2004, S. 215-220 Markus Rathey: Zur Datierung einiger Vokalwerke Bachs in den Jahren 1707 und 1708. BJ 2006, S. 65-92 Tatjana Schabalina: "Texte zur Music" in Sankt Petersburg. Neue Quellen zur Leipziger Musikgeschichte sowie zur Kompositions- und Aufführungstätigkeit Johann Sebastian Bachs. BJ 2008, S. 33-98 Vergleiche auch: Hans-Joachim Schulze: Die Bach-Kantate "Nach dir, Herr, verlanget mich" und ihr Meckbach-Akrostichon. BJ 2011, S. 255-258
APA, Harvard, Vancouver, ISO, and other styles
16

Krim, Arthur. "THE CARIBBEAN BEFORE COLUMBUS. By William F. Keegan and Corinne F. Hofman. xx and 332 pp.; maps, ills, bibliog., index. New York. Oxford University Press, 2017. $105.00 (cloth), isbn 9780190605257; $29.95 (paper), isbn 9780190605254; $14.39 (ebook) lccn 2016021992." Geographical Review 109, no. 1 (January 1, 2019): 148–50. http://dx.doi.org/10.1111/gere.12301.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Reichenbach, M., F. A. Habermann, H. D. Reichenbach, T. Guengoer, F. Weber, H. Zerbe, F. Sinowatz, A. Pfeifer, and E. Wolf. "432 INHERITANCE OF LENTIVIRAL PHOSPHOGLYCERATE KINASE-ENHANCED GREEN FLUORESCENT PROTEIN (PGK-eGFP) INTEGRANTS OF TRANSGENIC CATTLE." Reproduction, Fertility and Development 22, no. 1 (2010): 373. http://dx.doi.org/10.1071/rdv22n1ab432.

Full text
Abstract:
An alternative approach to classic techniques for the generation of transgenic livestock is the use of viral vectors. Using lentiviral vectors (LV) we previously generated transgenic founder cattle with integrants carrying phosphoglycerate kinase (PGK) promoter-enhanced green fluorescent protein (eGFP) expression cassettes (Hofmann et al. 2004 Biol. Reprod. 71, 405-409). The aim of this work was to investigate the transmission of LV-PGK-eGFP integrants through the female and male germ line of transgenic founder cattle in resulting embryos, fetuses, and offspring. The female founder animal was superovulated and artificially inseminated with a nontransgenic bull. Six of the 16 embryos obtained were transferred to synchronized recipient heifers, resulting in 2 pregnancies and birth of 1 healthy male transgenic calf, expressing eGFP as detected by in vivo imaging and real-time PCR. Cryopreserved semen of the founder bull and matured COC of nontransgenic cows were used for in vitro embryo production as previously described by Hiendleder et al. (2004 Biol. Reprod. 71, 217-223). The rates of cleavage and development to blastocysts in vitro corresponded to 52.3 ± 3.8% and 23.5 ± 4.6%, respectively. In vivo expression of eGFP was observed at blastocyst stage (Day 7 after IVF) and was seen in 93.8% (198/211) of all blastocysts. Twenty-four eGFP-positive embryos were transferred to 9 synchronized recipients. Analysis of 2 embryos flushed on Day 15, 2 fetuses recovered on Day 45, and a healthy male transgenic calf revealed consistent high-level expression of eGFP in all tissues investigated. These observations show for the first time transmission of lentiviral integrants through the germ line of female and male transgenic founder cattle. Although eGFP transgenic cattle have been produced before by nuclear transfer from transfected cells, lentiviral transgenesis has the advantage that only one copy of the provirus is integrated at a particular chromosomal integration site. High-fidelity expression of eGFP in embryos, fetuses, and offspring of founders provides an interesting tool for developmental studies in cattle, including interactions of gametes, embryos, and fetuses with their maternal environment.
APA, Harvard, Vancouver, ISO, and other styles
18

VAREY, J. E. "Hans Flasche and Gerd Hofmann, "Konkordanz zu Calderón. Concordancia aplicada a las obras de Calderón con auxilio de una computadora electronica. Computerized Concordance to Calderón" (Book Review)." Bulletin of Hispanic Studies 62, no. 4 (October 1985): 393. http://dx.doi.org/10.3828/bhs.62.4.393.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Behrens, F., G. R. Burmester, M. Feuchtenberger, H. Kellner, C. Kühne, A. Liebhaber, M. Sieburg, et al. "FRI0054 CHANGES IN DEPRESSIVE SYMPTOMS IN RHEUMATOID ARTHRITIS (RA) PATIENTS DURING TOCILIZUMAB (TCZ) THERAPY: THE GERMAN NONINTERVENTIONAL ARATA STUDY." Annals of the Rheumatic Diseases 79, Suppl 1 (June 2020): 603.2–603. http://dx.doi.org/10.1136/annrheumdis-2020-eular.4535.

Full text
Abstract:
Background:Depression is a common comorbidity in patients with RA and influences perception of disease activity and quality of life. We have previously reported that mean depression scores improved during TCZ therapy in conjunction with reductions in disease activity.1Objectives:To evaluate individual changes in depressive symptoms over 52 weeks in RA patients initiating treatment with TCZ.Methods:We analyzed data from a large German multicenter observational study of patients with active RA who initiated TCZ therapy during routine clinical care (ML29087 ARATA study;NCT02251860). The Beck Depression Inventory-II (BDI-II), a self-report questionnaire for depression screening that has been validated in RA, was used to assess symptoms of depression. Patients were classified by baseline BDI-II scores into depression categories of no (BDI-II<14), mild (BDI-II 14-19), moderate (BDI-II 20-28), and severe depression (BDI-II≥29).2Individual changes in BDI-II scores between baseline and week 52 were assessed. Erythrocyte sedimentation rate was used as the acute phase reactant in Disease Activity Score-28 joints (DAS28) assessments.Results:Of 1155 patients enrolled from 108 clinical centers in Germany between May 2014 and July 2018, 474 completed the BDI-II at baseline (BDI-II cohort); baseline characteristics were similar to those of patients who did not complete the BDI-II. Approximately half of patients in the BDI-II cohort had BDI-II scores indicating no depression (248; 52.3%); the remaining patients had mild (87; 18.4%), moderate (84; 17.7%), or severe (55; 11.6%) depression. The mean (SD) baseline characteristics of the BDI-II cohort were 55.5 (12.5) yrs of age, 75.7% female, 10.6 (9.2) yrs RA duration, 4.9 (1.2) DAS28, and 24.3 (10.2) Clinical Disease Activity Index (CDAI). Baseline DAS28 and CDAI scores were similar among different depression subgroups, but patients with severe depression were more likely to be female (87.3% vs 70.6% for no depression) and had higher levels of anxiety, suicidal ideation, fatigue, pain, and sleep disturbance than patients with no or milder depression.A total of 229 of the 474 patients (48.3%) in the BDI-II cohort completed the BDI-II at both baseline and week 52. At 52 weeks, the depression category of approximately half of patients with depressive symptoms at baseline changed to a lower level or no depression (Figure 1). Moderate to large improvements in BDI-II from baseline (>10 points) were reported by 33.3% to 38.5% of patients with baseline depressive symptoms (Figure 2).Conclusion:At 52 weeks after initiating TCZ, the depressive disease burden was reduced. Future analyses with a representative patient cohort will be aimed at exploring whether improvements in depression occur independent of reductions in disease activity.References:[1]Behrens F et al.Arthritis Rheumatol2019;71(suppl 10):abstr1414.[2]Smarr KL, Keefer AL.Arthritis Care Res2011;63(S11):S454-66.Acknowledgments:This study was sponsored by Chugai Pharma Germany GmbH and Roche Pharma AG. Sharon L. Cross and Kirsten Dahm provided medical writing services supported by Chugai. Statistical analyses were provided by Roche Pharma AG.Disclosure of Interests:Frank Behrens Grant/research support from: Pfizer, Janssen, Chugai, Celgene, Lilly and Roche, Consultant of: Pfizer, AbbVie, Sanofi, Lilly, Novartis, Genzyme, Boehringer, Janssen, MSD, Celgene, Roche and Chugai, Gerd Rüdiger Burmester Consultant of: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Speakers bureau: AbbVie Inc, Eli Lilly, Gilead, Janssen, Merck, Roche, Pfizer, and UCB Pharma, Martin Feuchtenberger Consultant of: Abbvie, BMS, Chugai, Sanofi, Speakers bureau: Abbvie, BMS, Celgene, Chugai, Jansen-Cilag, Lilly, Pfizer, Roche, Sanofi, UCB, Herbert Kellner: None declared, Cornelia Kühne Grant/research support from: Novartis, Amgen, Roche/Chugai, Pfizer, Celgene, AbbVie, Sanofi, Anke Liebhaber: None declared, Maren Sieburg: None declared, Siegfried Wassenberg: None declared, Christina Luig Employee of: Roche Pharma AG, Michael W. Hofmann Employee of: Chugai Pharma Germany GmbH, Christopher Amberger Grant/research support from: Chugai Pharma Germany GmbH, Consultant of: Chugai Pharma Germany GmbH
APA, Harvard, Vancouver, ISO, and other styles
20

Zimmer, A., A. Klein, K. Minden, T. Hospach, F. Weller-Heinemann, J. Kuemmerle-Deschner, M. Fasshauer, et al. "POS0075 SAFETY AND EFFICACY OF GOLIMUMAB FOR THE TREATMENT OF POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS - AN UPDATE FROM THE BIKER REGISTRY." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 244–45. http://dx.doi.org/10.1136/annrheumdis-2021-eular.2145.

Full text
Abstract:
Background:Golimumab (GOL) is approved for treatment of polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years and older. Data on long-term safety of GOL in this indication are limited.Objectives:To assess long-term safety and efficacy of GOL in pJIA patients.Methods:In this ongoing non-interventional observational study, clinical characteristics, disease activity and safety parameters were analysed using the German Biologics in Paediatric Rheumatology (BiKeR) registry. 81 pJIA-patients treated with GOL were body weight-matched with 162 patients receiving alt. tumor necrosis factor inhibitors (TNFi) and 81 biologic–naïve patients under methotrexate (MTX)-therapy.Results:Baseline parameters of GOL patients differed from the alternative TNFi and MTX cohorts. In patients starting with GOL treatment, disease duration was longer, corticosteroid use was less and disease activity, measured by the mean number of active joints and the JADAS10, was lower (Table 1).The long-term clinical efficacy of GOL in pJIA is highlighted by a decrease of the mean JADAS 10 from 11.6 (baseline) to 5.2 after 24 months. After 2 years, a JADAS 10 minimal disease activity was reached by 44.4 % of patients, whereas 22.2 % of patients were in remission and the JIA ACR 30/50/70/90 response rates were 77.8/72.2/66.7/55.6% respectively.AE, SAE and infectious AE rates between the three cohorts were comparable (Table 1). In the GOL cohort, 4 SAE (1 uveitis, 1 arthritis flare, 1 fibromyalgia syndrome and 1 abscess) were reported, while in the alt. TNFi group 7 SAEs and in the MTX cohort 1 SAE were noted (Table 1). One serious infectious event (1 abscess) was documented in the GOL cohort, 2 alt. TNFi patients had influenza and no serious infectious events were seen in the MTX control group.Table 1.Baseline parameters and adverse eventsGOLn=81alt. TNFin=162MTXn=81p-value ∞GOL vs alt. TNFip-value∞ GOL vs MTXGender female °67 (83)127 (78)64 (79)0.50.7Disease duration (yrs)7.1±4.34.3±3.71.2±2.1<0.0001<0.0001RF neg. Polyarthritis °40 (49)79 (49)50 (62)1.00.15RF pos. Polyarthritis °8 (10)22 (14)16 (20)0.50.1Extended Oligoarthritis °30 (37)54 (33)13 (16)0.60.004Psoriatic arthritis °3 (4)7 (4)2 (3)1.0/1.01.0Pretreatment bDMARD °68 (84.0)35 (21.6)0<0.0001<0.0001Concomitant systemic steroids, n (%)13 (16)38 (24)39 (48)0.2<0.0001Active joint count #4.6±4.84.9±5.79.6±6.50.4<0.0001CHAQ DI #0.4±0.50.5±0.50.6±0.60.10.02JADAS10 #11.6±6.212.1±6.116.8±5.30.6<0.0001AE *91 (107.4; 88-132)213 (88.7; 78-101)113 (119.8; 100-144)0.10.4SAE *4 (4.7; 2-13)7 (2.9; 1-6)1 (1.1; 0.1-8)0.40.2Serious infections *1 (1.2; 0.2-8.4)2 (0.8; 0.2-3.3)00.7n.a.Autoimmune process (%)2 (2.4)3 (1.9)1 (1.2)1.01.0Patients with uveitis new manifestation after study entry *1 (1.2; 0.2-8)2 (0.8; 0.5-3)00.7n.a.Patients with uveitis flare events with preexisting uveitis at baseline*6 (7.1; 3-16)00n.a.n.a.Rheumatoid factor (RF), biologic disease modifying antirheumatic drug (bDMARD), childhood health assessment questionnaire disability index (CHAQ Di), juvenile arthritis disease activity index (JADAS), adverse event (AE), patient year (PY), ° n (%), # mean (SD), * n (rate/100PY; 95%CI), Golimumab (GOL), alternative tumor necrosis factor inhibitor (alt. TNFi), methotrexate (MTX), ∞ by t-test or χ2-test as appropriate.Few autoimmune processes occurred: 2 incident events in the GOL cohort (1 uveitis, 1 psoriasis), 3 cases in the alt. TNFi group (2 uveitis, 1 psoriasis,) and 1 event in MTX-patients (celiac disease) (Table 1). Out of the 20 GOL patients with preexisting uveitis at baseline, 6 had flare events; there were no reported uveitis flares of the 17 patients in the alt. TNFi group and no patients with preexisting uveitis in the MTX-group. No malignancies or deaths were reported.Conclusion:Our interim results show an acceptable safety profile of GOL therapy, comparable to treatment with alt. TNFi or MTX. No new safety signals occurred. The efficacy outcome data confirm long-term benefits of GOL treatment in pJIA patients.Acknowledgements:We greatly appreciate the kind support of Z. Huang, S. Calhoun.Disclosure of Interests:Angela Zimmer: None declared, Ariane Klein: None declared, Kirsten Minden: None declared, Toni Hospach: None declared, Frank Weller-Heinemann: None declared, Jasmin Kuemmerle-Deschner: None declared, Maria Fasshauer: None declared, Nadja Hofmann: None declared, Hans Koessel: None declared, Ivan Foeldvari: None declared, Sonja Mrusek: None declared, Daniel Windschall: None declared, Nils Onken: None declared, Markus Hufnagel: None declared, Dirk Foell: None declared, Normi Brueck: None declared, Prassad Thomas Oommen: None declared, Frank Dressler: None declared, Astrid Helling-Bakki: None declared, Gerd Horneff Speakers bureau: MSD.
APA, Harvard, Vancouver, ISO, and other styles
21

Specker, C., M. Aringer, G. R. Burmester, M. Peters, M. W. Hofmann, H. Kellner, F. Moosig, H. P. Tony, and G. Fliedner. "POS0615 TOCILIZUMAB IS SAFE AND EFFECTIVE IN ELDERLY PATIENTS WITH RHEUMATOID ARTHRITIS." Annals of the Rheumatic Diseases 80, Suppl 1 (May 19, 2021): 544.2–545. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1711.

Full text
Abstract:
Background:Average life spans of patients with rheumatoid arthritis (RA) are approaching those of the general population. This results in a large proportion of RA patients being elderly at some point and underlines effective RA treatments needed for this population. Pivotal clinical trials have demonstrated the efficacy of tocilizumab (TCZ) for the treatment of RA. However, real-world studies that explore the effectiveness of TCZ especially in the elderly are lacking. ICHIBAN was a large, observational study that followed patients with RA treated with TCZ under real-world conditions in Germany for up to 2 years.Objectives:In this analysis of ICHIBAN, we examined the safety and effectiveness of long-term TCZ treatment according to patient baseline (BL) age (<50, 50–65, >65 years).Methods:ICHIBAN (NCT01194401) was a prospective, non-interventional study that observed adult patients with active moderate to severe RA in German rheumatology clinics and practices. Patients were treated with TCZ according to the local label. The safety analyses set (SAF) included all patients who received at least one dose of TCZ. The effectiveness set (EFF) included all patients from the SAF who had no prior TCZ therapy. Patient-reported outcomes (PROs) were assessed using the visual analogue scale. Last observation carried forward was used to substitute for missing values.Results:At baseline (BL), 3,164 patients were included in the SAF: 29.2% <50 years, 47.3% 50–65 years, and 23.5% >65 years old (1.2% ≥80 years). Patients >65 years old were not only the most likely to have comorbidities such as hypertension, anaemia, renal insufficiency, osteoporosis, diabetes, and coronary heart disease, but also had the highest BL disease activity according to Disease Activity Score-28 erythrocyte sedimentation rate (DAS28-ESR) and Clinical Disease Activity Index (CDAI) (Table 1).Proportions of patients with adverse events (AEs) considered related to treatment were similar in patients <50 (22.3%), 50–65 (21.9%) and >65 years (22.2%). More patients >65 years (20.2%) and 50–65 years (14.4%) experienced serious AEs (SAEs) than patients <50 years (11.5%). Slightly more patients >65 years old experienced infectious SAEs (4.8%) than younger patients (<50 years, 3.2% and 50–65 years, 3.1%). Yet, similar proportions of patients across all age groups discontinued TCZ due to AE (7.0% <50 years; 9.6% 50–65 years; 7.8% >65 years).2,902 patients were included in the EFF. Patients <50 years experienced DAS28-ESR remission at least once during the treatment period (65.4%) more often than patients aged 50–65 years (59.8%) or >65 years (59.5%). However, patients >65 years had numerically greater improvements in DAS28-ESR (Table 1). Patients <50 years had the best physical functioning at BL and the greatest reduction in Health Assessment Questionnaire Disease Index (HAQ-DI) score (Figure 1A). All age groups had similar improvements in PROs such as fatigue, strength of pain, and sleep disturbances (Figure 1B).Table 1.Model summary for prediction of DAS28CRP using time and etanercept originator (relative to biosimilar)<50 years50–65 years>65 yearsDAS28-ESR, mean ± SDn*7771237617BL4.9 ± 1.45.3 ± 1.35.4 ± 1.3Last visit2.8 ± 1.73.1 ± 1.73.2 ± 1.7Change from BL-2.0 ± 1.7-2.2 ± 1.7-2.2 ± 1.8CDAI, mean ± SDn*7681217590BL25.7 ± 12.828.4 ± 13.328.8 ± 12.8Last visit13.3 ± 12.814.6 ± 13.214.5 ± 12.8Change from BL-12.5 ± 13.6-13.8 ± 14.0-14.3 ± 13.8*271 patients with missing data at BL**327 patients with missing data at BLConclusion:Although elderly patients experienced a higher rate of infections, the proportion of patients withdrawing due to AE was not higher than in the other age groups. Starting with higher baseline disease activity, patients >65 years had similar benefits to disease activity and PROs when compared with younger patients. Overall, these results indicate that long-term TCZ treatment of elderly patients is effective and has an acceptable safety profile.Disclosure of Interests:Christof Specker Speakers bureau: AbbVie, Celgene, Chugai, Janssen-Cilag, Lilly, MSD, Novartis, Pfizer, Roche, and UCB, Consultant of: AbbVie, Boehringer Ingelheim, Chugai, Lilly, Novartis, Sobi, and UCB, Grant/research support from: Boehringer, Chugai, GSK, and Roche, Martin Aringer Speakers bureau: Roche and Chugai, Consultant of: Roche and Chugai, Grant/research support from: Roche, Gerd Rüdiger Burmester Consultant of: Lilly, Pfizer, Sanofi, and Roche, Grant/research support from: Roche, Marvin Peters Employee of: Roche Pharma AG, Michael W. Hofmann Employee of: Chugai Pharma Germany GmbH, Herbert Kellner Consultant of: Roche, Grant/research support from: Roche, Frank Moosig Grant/research support from: Roche, Hans-Peter Tony Speakers bureau: Roche, Abbvie, BMS, Chugai, Janssen, Novartis, Sanofi, and Lilly, Consultant of: Roche, Abbvie, BMS, Chugai, Janssen, Novartis, Sanofi, and Lilly, Grant/research support from: Roche, Gerhard Fliedner Grant/research support from: Roche, Chugai, Abbvie, and Lilly
APA, Harvard, Vancouver, ISO, and other styles
22

Joost, Ulrich. "Henning Boëtius, Der Gnom. Lichtenberg-Roman. — Gert Hofmann, Die kleine Stechardin." Arbitrium 13, no. 2 (1995). http://dx.doi.org/10.1515/arbi.1995.13.2.264.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

"German and European Poetics after the Holocaust: Crisis and Creativity. Ed. Gert Hofmann, Rachel MacShamhrain, Marko Pajevic & Michael Shields. Rochester NY/Woodbridge: Camden House, 2011. 310 pp. 40.00. ISBN 978-1-57113-290-1." Forum for Modern Language Studies 48, no. 4 (September 26, 2012): 489. http://dx.doi.org/10.1093/fmls/cqs046.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

"Topodynamics of Arrival: Essays on Self and Pilgrimage. Eds. Gert Hofmann and Snjezana Zori. Amsterdam & New York: Rodopi (Spatial Practices: An Interdisciplinary Series in Cultural History, Geography and Literature, 14), 2012. 242 pp. 52.00/$70.00. ISBN 9789042035386." Forum for Modern Language Studies 50, no. 1 (June 7, 2013): 133. http://dx.doi.org/10.1093/fmls/cqt021.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Steeman, Jan. "J.P. Hofman (1838-1894), Gents stadsingenieur-architect Oneervol ontslagen en … onterecht helemaal vergeten." Ghendtsche Tydinghen 50, no. 1 (January 1, 2021). http://dx.doi.org/10.21825/gt.85045.

Full text
Abstract:
Tussen 1866 en 1878 was Jean Pierre Hofman aan de slag bij de dienst van openbare werken van de Stad Gent. Vanaf 1873 stond hij er aan het hoofd als ingenieur-directeur. In die periode werd de dienst geconfronteerd met grote uitdagingen: de eerste plannen voor de uitbreiding van de voorhaven werden getekend, de wijk rond het Citadelpark werd ontwikkeld én de stad zou snel haar eerste tramlijnen krijgen. Aan de beloftevolle carrière kwam echter snel een einde toen Hofman ontslagen werd.
APA, Harvard, Vancouver, ISO, and other styles
26

Steeman, Jan. "Ontslag in 1878 van Jean Pierre Hofman, ingenieur-directeur van de stadswerken Gent." Ghendtsche Tydinghen 50, no. 2 (March 1, 2021). http://dx.doi.org/10.21825/gt.85052.

Full text
Abstract:
In dit artikel wordt nader ingegaan op de omstandigheden die na nauwelijks iets meer dan tien jaar tot zijn gedwongen ontslag leidden. Ze illustreren een veranderende mentaliteit in de stedelijke administratie. Hofman werd benoemd in 1867 in een periode dat die dienst herhaalde reorganisaties onderging. Pogingen werden ondernomen om de hogere ambtenaren ertoe te dwingen zich volledig aan hun taak te wijden en onafhankelijk van pressiegroepen en privéondernemingen te werken. Precies op dit vlak liep het mis voor Hofman. In 1878 werd hij in de gemeenteraad beschuldigd van belangenvermenging.
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography